The bill, known as The Matthew Federico Diabetic Safety Act, mandates that starting January 1, 2027, every individual or group health insurance contract, plan, or policy that provides prescription coverage and is delivered, issued for delivery, prescribed, or renewed in Rhode Island must include coverage for at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution. This coverage will allow individuals to obtain two glucagon auto-injectors, nasal spray, or non-reconstituted formulations each plan year without any copayment or deductible. However, a deductible may be applied to health plans that are paired with federally qualified health savings accounts. The act will take effect upon passage, with the specific provisions regarding coverage becoming enforceable in 2027.